SCHEDULE 14A INFORMATION Proxy Statement Pursuant To Section 14(a) Of The Securities Exchange Act Of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [_] Check the appropriate box: [_] Preliminary Proxy Statement [_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY RULE 14A-6(E)(2)) [_] Definitive Proxy Statement [X] Definitive Additional Materials [_] Soliciting Material Pursuant to Section 240.14a-12 ICN Pharmaceuticals, Inc. -------------------------------------------------------- (Name of Registrant as Specified in its Charter) N/A -------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. (1) Title of each class of securities to which transaction applies: ------------------------------------------------------------------- (2) Aggregate number of securities to which transaction applies: ------------------------------------------------------------------- (4) Proposed maximum aggregate value of transaction: ------------------------------------------------------------------- (5) Total fee paid: ------------------------------------------------------------------- [_] Fee paid previously with preliminary materials. [_] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: ------------------------------------------------------------------- (2) Form, Schedule or Registration Statement No.: ------------------------------------------------------------------- (3) Filing Party: ------------------------------------------------------------------- (4) Date Filed: ------------------------------------------------------------------- Following is the text of materials ICN used in presentations to stockholders on May 22, 2001. The Medical Economics article was reproduced with the consent of the editor for use as proxy soliciting materials. Copyright (C) 2001 by Medical Economics Company. Reproduced by permission from Medical Economics magazine. Website: www.memag.com MEDICAL ECONOMICS THE BUSINESS MAGAZINE OF THE MEDICAL PROFESSION (COPYRIGHT) APRIL 9, 2001 25 top health care stocks will they lead the next market boom? [PICTURE OMITTED - SECTION OF DNA DOUBLE HELIX] Keep your practice alive when the computer goes dead ----------------------- Your nest egg just got bigger ----------------------- Was I doing my duty-or ratting on a colleague? BEST HEALTH CARE STOCKS 52-WEEK RECENT P-E TICKER HIGH-LOW PRICE RATIO ------ -------- ----- ----- Accredo Health ACDO 37-12 26 48 Amgen AMGN 80-50 65 62 Applied Biosystems ABI 133-143 50 50 Aradigm ARDM 39-6 6 N/A ArQule ARQL 35-6 14 57 Biomet BMET 42-18 40 40 CardioDynamics International CDIC 13-2 3 N/A Chiron CHIR 59-33 44 N/A Cigna CI 137-61 111 18 Cor Therapeutics CORR 67-22 28 N/A Eli Lilly LLY 109-57 78 28 Genentech DNA 100-42 46 N/A Genzyme (General Division) GENZ 104-40 86 69 Human Genome Sciences HGSI 107-25 48 N/A ICN Pharmaceuticals ICN 42-21 24 N/A Icos ICOS 60-27 46 N/A ImClone Systems IMCL 69-26 30 N/A Johnson & Johnson JNJ 106-69 94 28 Medtronic MDT 62-45 47 46 Merck MRK 97-55 73 25 Myriad Genetics MYGN 138-19 43 N/A Pfizer PFE 49-33 40 43 Pharmacia PHA 64-39 49 76 St. Jude Medical STJ 65-24 51 34 Waters WAT 91-37 51 44 All data as of March 31, 2001. Stocks with four-letter tickers trade on Nasdaq. All others trade on New York Stock Exchange. N/A: Not Available, because the company has no earnings or its P-E ratio is too high to be meaningful. Source: Dow Jones ICN PHARMACEUTICALS makes and sells nutritional and pharmaceutical products that treat viral and bacterial infections, skin diseases, neuromuscular disorders, cancer, heart disease, diabetes, and psychiatric disorders. Its leading anti-viral agent, Virazole, is approved in 43 countries to combat diseases including flu, herpes, and HIV. Royalties for Rebetron, an anti-viral drug used to treat hepatitis patients, were expected to reach $160 million last year. An estimated 2 percent of the world's population is infected with hepatitis C. The company is introducing a more efficient version of the drug, and it plans to start selling Rebetron in Japan. ABOUT THESE COMPANIES Segment An expert says... ------- ----------------- HUMAN GENOME SCIENCES Biotechnology "This stock is for the risk-tolerant; it has high upside potential." (Mireskandari) ICN PHARMACEUTICALS Pharmaceuticals "Look for strong gains from this excellent company." (Yellen) ICOS Pharmaceuticals "Could be a real winner in both the short and the long term." (McCamant) IMCLONE SYSTEMS Pharmaceuticals "Excellent management and advanced science could make share price soar, and it's a good buy right now." (McCamant) JOHNSON & JOHNSON Pharmaceuticals "Won't grow 30 percent a year like the small, new companies, but I can see 12 to 14 percent annual returns." (Duarte) MEDTRONIC Medical supplies "Almost a can't miss; a great company that can bring top returns." (Duarte) MERCK Pharmaceuticals "A good stock to buy at any time." (Duarte) MYRIAD GENETICS Biotechnology "Stands a good chance of 25 percent annualized returns, but could be risky." (Mireskandari) PFIZER Pharmaceuticals "Stock price has more than doubled in the past five years [accounting for splits], and should do very well in the coming decade." (Mireskandari) PHARMACIA Pharmaceuticals "Share price could increase in the range of 15 percent annualized in the next decade." (Mireskandari) ST. JUDE MEDICAL Medical Supplies "It has a great deal of growth potential, and is one of the most underrated companies in medical equipment." (Duarte) WATERS Medical Supplies "If you can buy on a dip, this growth stock could double in price within a couple of years." (Borzilleri) [LOGO - NLITE(TM) LASER COLLAGEN REPLENISHMENT] FOR PERIOCULAR WRINKLE REDUCTION WE ARE PLEASED TO PROVIDE THE NLITE LCR LASER, AS CLEARED BY THE FDA, FOR NON-ABLATIVE PERIOCULAR WRINKLE REDUCTION. Another anti-aging solution from ICN Pharmaceuticals, Inc. [PHOTO OMITTED - BEFORE] [PHOTO OMITTED - SINGLE TREATMENT] LASER TYPE: Pulsed Dye Laser WAVELENGTH: 585 nm PULSE CHARACTERISTICS: Pulse Duration: 350 us Spot Size: 5 mm Repetition Rate: 2 hz, Software Controlled BEAM DELIVERY: Lens-Coupled Flexible Optical Fiber with Handpiece AIMING BEAM: Laser Type: 0.8 mW Diode Laser, Class II Wavelength: 670 nm (red) MODE STRUCTURE: Top Hat, +2% of Mean SMARTRIDGEDYE LIFE: 50,000 Pulses LASER COOLING METHOD: Self Contained De-ionized Water Cooled Integral Chiller SIZE: 24" x 36" x 41" ELECTRICAL REQUIREMENTS: 220-240 VAC, 25A 50/60 Hz, Single Phase USER INTERFACE: Colar LCD withTouch Screen Interface ENVIRONMENTAL REQUIREMENTS: 10 degrees C to 30 degrees C Non-Condensing Humidities below 75% RH. SAFETY: Class IV Laser The NLite LCR(TM) Laser triggers collagen replenishment without general tissue stimulation or irritation. Clinical studies of the NLite LCR(TM) Laser indicate collagen growth with shorter treatment cycles than existing technologies. Clinical studies report 84% comparable results to CO2 laser therapy for periocular wrinkle reduction with no downtime. Post treatment reports indicate virtually no side effects, no hypopigmentation or hyperpigmentation. Does not require the use of a surface cooling device. [PICTURE OMITTED - NLite LCR (TM) Laser] For more information, please contact: 800-256-3399 www.NLiteLCR.com [LOGO - ICN / ICN MEDICAL ALLIANCE, INC.] [LOGO - DANGER] ICN Pharmaceuticals, Inc. 2001 In addition to providing the NLite LCR(TM) System for periocular wrinkle reduction, ICN Medical Alliance is proud to offer you the following aesthetic lasers on a daily-access basis: ----------------------------------------------------------- FULL OFFERING OF PREMIER LASERS WITH TECHNICAL SUPPORT: Ultra Pulse CO2 Erbium:YAG Aura KTP/532 with Cooler Alexandrite Flashlamp Pulsed Dye Q-Switched Frequency Doubled ND:YAG Apogee 6200 Alexandrite ----------------------------------------------------------- ----------------------------------------------------------- PATIENT INDICATIONS: Facial Wrinkles Pigmented Lesions Birthmarks Facial and Body Hair Acne Scars Tattoos Puffy Eyelids Facial and Leg Veins Vascular Lesions ----------------------------------------------------------- ----------------------------------------------------------- ICN PHARMACEUTICAL SKINCARE PRODUCTS: Glyquin - 4% Hydroquinone with 10% glycolic acid Kinerase - Topical anti-aging lotion or cream with N6-furfuryladenine Glyderm - Esterified glycolic acid line of peels, cleansers, and moisturizers ----------------------------------------------------------- WHY CHOOSE ICN MEDICAL ALLIANCE? 1. The Only National Office-Based Aesthetic Surgical Services Company 2. Convenient Scheduling 3. Extensive Insurance Coverage 4. State-of-the-Art Technology 5. Unmatched Experience 6. Commitment to Quality 7. Trained Technicians 8. Physician Education Programs 9. Office Staff Education 10. Patient Education 11. Aesthetic Surgery Network 12. Practice Building and Marketing Support 13. The only company to provide a total skincare solution Also available: The Rejuvasilk(TM) Microdermabrasion System. Call for a free demo! 800-256-3399 www.NLiteLCR.com